BRIEF-Infinity Pharma says new preclinical data show IPI-549 can reverse tumor resistance to checkpoint inhibitors
September 26, 2016 at 17:23 PM EDT
* Announced data for ipi-549, orally administered immuno-oncology development candidate that selectively inhibits pi3k-gamma